What is the Role of Glycopeptides in Intensive Care?;Quale Ruolo per i Glicopeptidi in Terapia Intensiva?

Journal of Chemotherapy

Volumn 15, Issue SUPPL. 1, 2003, Pages 11-16

  Esposito, S ^a,b   Noviello, S ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Ospedale Gesu e Maria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ARTIFICIAL VENTILATION; CATHETER INFECTION; CONFERENCE PAPER; ENTEROCOCCUS; HUMAN; INTENSIVE CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG EFFECTS; INCIDENCE; INTENSIVE CARE UNIT; RISK FACTOR; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CAUSE OF DEATH; GRAM POSITIVE BACTERIUM; MICROFLORA; SIDE EFFECT; STAPHYLOCOCCUS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; HUMANS; INCIDENCE; INTENSIVE CARE UNITS; RISK FACTORS;

EID: 0346102804     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2003.11782354     Document Type: Conference Paper

References (26)

1. Weinstein RA. Epidemiology and control of nosocomial infections in adult intensive care units. Am J Med 1991; 91: 179-184.
2. Kappstein I, Daschner FD. Nosocomial infections in intensive care units. Curr Opinion Infect Dis 1990; 3: 509-516.
3. Wenzel RP, Thompson RL, Landry SM et al. Hospital-acquired infections in intensive care units: an overview with e emphasis on epidemics. Infect Control 1993; 4: 371-375.
4. Jarvis WR, Edwards JR, Culver DH et al. Nosocomial infection rate in adult and paediatric intensive care units in United States. Am J Med 1991; 91: S3B, 185-191.
5. Weber DJ, Raasch R, Rutala WA. Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens. Chest 1999; 115, (3 suppl.): 34-41.
6. Vincent JL, Bihari D, Suter PM et al. The prevalence of nosocomial infections in intensive care units. Results of the European Prevalence of Infection in Intensive Care. (EPIC) Study. JAMA 1995; 274: 639-644.
7. Diekema DJ, Pfaller MA, Schmicz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in United States, Canada, Latin America, Europe and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 15, 32, suppl. 2: 114-132.
8. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospital patients. Clin Infect Dis 2000; 31, suppl 4: 131-138.
9. Kollef MH. Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections. Chest, 115, 462-474, 1999
10. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of S. aureus infections in New York city hospitals. Emerg Infect Dis 1999; 5: 9-17.
11. Wood M. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
12. Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomised prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989; 33: 1193-1197.
13. Kureshi A, Jewesson PJ, Rubinger M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporine A-associated nephrotoxicity. Antimicrob Agents Chemother 1991; 35: 2246-2252.
14. Charbonneau P, Harding I, Garraud JJ, Aubertin J, Brunet F, Domart Y. Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Med 1994; 20, Suppl. 4: S35-42.
15. Neville LO, Brumfitt W, Hamilton-Miller JMT, Harding I. Teicoplanin vs vancomycin for the treatment of serious infections: a randomised trial. Int J Antimicrob Agents 1995; 5: 187-193.
16. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with telcoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
17. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised patients. Antmicrob Agents Chemother 1991; 35: 451-457.
18. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother 1988; 21, Suppl A: 81-87.
19. th ICAAC 1987, Abstr. 1039, p. 278.
20. Cony-Makhoul P, Brossard G, Marit G, Pellergrin JL, Texier-Maugein J, Reiffers J. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol 1990; 76, Suppl 2: 35-40.
21. th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 1995. Abstr. 760, p. 232.
22. Kulmala HK, Heilman CJ, Kuzma RJ, Sullivan WA, Stephens GJ, Rios I. A randomised, blinded, comparative study of teicoplanin versus vancomycin in the treatment of vascular-access-associated bacteremia/septicaemia caused by Gram-positive bacteria (Protocol 102-009). Data on file, Marion Merrell Dow.
23. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen in febbrile, neutropenic patients with haematological malignancies. Antimicrob Agents Chemother 1994; 38: 2041-2046.
24. Trinidad C, Nestora M. A study of teicoplanin and vancomycin in combination therapy for febrile episodes in neutropenic paediatric patients. (19th ICC, Montreal; July 1995) Can J Infect Dis 1995; 6, suppl C: 309 C.
25. Liu C-Y, Lee W-S. Comparative study of teicoplanin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Drug Invest 1996; 12: 80-7.
26. Choi JY, Kim YR. A randomized study comparing clinical efficacy of ceftazidime plus aztreonam plus teicoplanin or vancomycin regimen in febrile granulocytopenic patients. J Korean Soc Chemother 1992; 10: 165-171.